Treatment of HIV-associated Kaposi's sarcoma with paclitaxel.

  title={Treatment of HIV-associated Kaposi's sarcoma with paclitaxel.},
  author={Margaret Saville and J A Lietzau and James M. Pluda and Irwin Feuerstein and Jeanne Odom and Wyndham H. Wilson and Rick Humphrey and E Feigal and Seth Steinberg and Samuel E Broder},
  volume={346 8966},
We investigated whether paclitaxel was active in AIDS-associated Kaposi's sarcoma. We gave 135 mg/m2 intravenously over 3 hours every 21 days. Follow-up is available on the first 20 patients, most of whom had advanced Kaposi's sarcoma and severe immunocompromise. Neutropenia was the most frequent dose-limiting toxic effect; novel toxic effects included late fevers, rash, and eosinophilia. Creatinine increased in 2 patients and 1 patient had cardiomyopathy. There were 13 partial responses (65… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 46 extracted citations

Cytokinetic study of MCF-7 cells treated with commercial and recombinant bromelain.

Asian Pacific journal of cancer prevention : APJCP • 2014
View 3 Excerpts
Highly Influenced

Dynamic remodeling of context-specific miRNAs regulation networks facilitate in silico cancer drug screening

2011 IEEE International Conference on Systems Biology (ISB) • 2011
View 11 Excerpts
Highly Influenced

Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies.

Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy • 2016
View 1 Excerpt

Similar Papers

Loading similar papers…